Latest filing published 04 Mar 2025 for Cara Therapeutics, Inc., €746. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Scott Terrillion in Tvardi Therapeutics, Inc., where the filings describe the role as chief executive. In total, 15 filings cover trades dated from 24 August 2021 to 28 February 2025.
Sales make up the whole of the open-market record (11 sales, €170k). Other entries cover 4 share grants. 2025 to date brings no purchases and 1 sale.
Most recently, on 4 March 2025, the filings show an open-market sale worth €746 in Tvardi Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
15 of 15 declarations